


# Nedosiran Clinical Development Program



Abbreviations: ESKD=end-stage kidney disease; Uox=urinary oxalate, PH=primary hyperoxaluria, N=number. † = PH3 patient enrollment not open in the US  
 References: 1. Hoppe B, et al. *Kidney Int.* 2022;101(3):626-634. 2. [ClinicalTrials.gov identifier: NCT03392896](https://clinicaltrials.gov/ct2/show/NCT03392896). Accessed March 9, 2023. 3. [ClinicalTrials.gov identifier: NCT03847909](https://www.clinicaltrials.gov/ct2/show/record/NCT03847909). Accessed May 20, 2022. 4. Baum MA, Langman C, Cochran P, et al. *Kidney Int.* 2023;103(1):207-217. 5. [ClinicalTrials.gov identifier: NCT04042402](https://www.clinicaltrials.gov/ct2/show/study/NCT04042402). Accessed July 16, 2021. Accessed May 23, 2022. 6. [ClinicalTrials.gov identifier: NCT04555486](https://www.clinicaltrials.gov/ct2/show/study/NCT04555486). Accessed September 10, 2021. Accessed May 23, 2022. 7. News release. Business Wire; October 19, 2021. <https://dicema.com/wp-content/uploads/2022/04/Dicerna-Announces-Results-for-PHYOX-4-Single-Dose-Study-of-Nedosiran-in-Primary-Hyperoxaluria-Type-3-PH3.pdf>. Accessed May 23, 2022. 8. [ClinicalTrials.gov identifier: NCT04580420](https://www.clinicaltrials.gov/ct2/show/study/NCT04580420). Updated July 8, 2021. Accessed May 20, 2022. 9. [ClinicalTrials.gov identifier: NCT05001269](https://www.clinicaltrials.gov/ct2/show/study/NCT05001269). Updated September 10, 2021. Accessed May 20, 2022. 10. [ClinicalTrials.gov identifier: NCT04542590](https://www.clinicaltrials.gov/ct2/show/study/NCT04542590). Updated November 18, 2021. Accessed May 23, 2022. 11.